Generic drugmaker Perrigo Company announced that its Board of Directors unanimously rejected Mylan’s unsolicited $29 billion takeover bid, claiming that the proposal substantially undervalues the company. Earlier this month, Mylan offered $205 per share in cash and stock for the Dublin-based company. Perrigo said Tuesday that the previous offer undervalues …